MAPT and Alzheimer disease: In addition, we observed strong trends toward increased sleep percentages (1400–1700 hours) in both AD-tau–injected and non–AD-tau–injected APPPS1:E3 mice after 8 weeks of SD treatment compared with the first week of SD (Supplemental Figure 4, A and B).